Syros raises $40M to get its leukemia drug into Phase II

Damian Garde

Pharmaceuticals raised $ 40 million in equity to push forward with its pipeline of genetically targeted drugs, securing the cash it needs to take its top prospect II.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS